Introduction {#sec1-1}
============

Multiple primary malignancies are occurring more frequently than before and the incidence of second primary cancers varies from 1 to 16% depending on the index primary cancer.\[[@ref1]\] We should be aware of the pathogenesis of multiple primary malignancies as some people are more susceptible to have multiple cancers.\[[@ref2]\] Several authors mentioned the co-occurrence of two primary cancers, namely breast cancer and thyroid cancer.\[[@ref2][@ref3][@ref4][@ref5]\] The concurrent occurrence of thyroid cancer and malignant brain tumor was rarely seen.\[[@ref6]\] We are describing a young Caucasian female patient who was diagnosed with two synchronous cancers, glioblastoma multiforme (GBM) and papillary thyroid cancer (PTC).

Case Report {#sec1-2}
===========

A 19-year-old Caucasian female patient without significant medical history presented to the emergency room with symptoms of dizziness, headache and emesis. She denied any smoking or alcohol history. She denied any history of head trauma or bleeding diathesis. Family history was positive for breast cancer and lymphoma in maternal grandmother, but no reported history of thyroid malignancy. Her Glasgow coma scale score was 15. On neurological examination, motor strength was five over five in all extremities. Cranial nerves II to XII were intact. Sensations to touch and pain were intact. Finger to nose test was normal and there was no ataxia. Complete blood count and liver function tests were within a normal range.

CT head \[[Figure 1a](#F1){ref-type="fig"}\] revealed acute intraparenchymal hematoma in the right cingulate gyrus and the splenium of the corpus callosum measuring 4.1 × 3.4 cm in size, with extension of hemorrhage into the ventricular system resulting in mild dilatation of the temporal horn of the right lateral ventricle. Carotid and cerebral angiogram were unremarkable. MRI of brain \[[Figure 1b](#F1){ref-type="fig"} and [1c](#F1){ref-type="fig"}\] demonstrated a non-enhancing and non-hemorrhagic component of the lesion along the lateral margin of the hemorrhage that was suspicious for a tumor. Subsequently, the patient developed hydrocephalus and she underwent sub-temporal craniotomy with the placement of a ventricular drain into the right temporal horn. Cerebrospinal fluid analysis was negative for flow cytometry and cytology.

![(a) CT head showing intraparenchymal hematoma in the right cingulate gyrus and the splenium of the corpus callosum. (b and c) MRI head demonstrated a non-enhancing and non-hemorrhagic component of the lesion along the lateral margin of the hemorrhage just medial to the atrium of the right lateral ventricle](JNRP-6-241-g001){#F1}

CT chest, abdomen, and pelvis revealed a 11 mm hypodense lesion in the left lobe of the thyroid \[[Figure 2a](#F2){ref-type="fig"}\]. The patient has not been symptomatic with respect to thyroid. Ultrasonogram of thyroid \[[Figure 2b](#F2){ref-type="fig"}\] confirmed the presence of a hypoechoic nodule in the superior aspect of the left lobe of the thyroid measuring 14 × 11 × 11 mm in size. No blood flow was observed within the nodule. MRI of brain performed four days after admission \[[Figure 3a](#F3){ref-type="fig"}\] showed a heterogenous, hemorrhagic parasagittal right parieto-occipital brain lesion of 39 × 31 mm with extension into the splenium of corpus. MRI of brain showed further evolution of the hemorrhagic lesion on the 11^th^ day after admission \[[Figure 3b](#F3){ref-type="fig"}\]. There were multiple areas of enhancement within the lesion with the largest area noted along the superior margin.

![(a) CT chest demonstrating a 11 mm hypodense lesion in the left lobe of thyroid. (b) Ultrasonogram of thyroid confirmed the presence of a hypoechoic nodule in the superior aspect of the left lobe of the thyroid](JNRP-6-241-g002){#F2}

![(a and b) MRI of brain showed a heterogenous, hemorrhagic parasagittal right parieto-occipital brain lesion of 39 × 31 mm with extension into the splenium of corpus callosum. (c) CT head showing right parafalcine mass measuring 3.8 cm](JNRP-6-241-g003){#F3}

CT head \[[Figure 3c](#F3){ref-type="fig"}\] done on the same day confirmed right parafalcine mass measuring 3.8 cm, mostly isodense to adjacent brain, situated off the posterior superior aspect of splenium displacing the right lateral ventricle outward and abutting the falx. Brain biopsy was performed and pathology report confirmed it as GBM \[[Figure 4a](#F4){ref-type="fig"} and [b](#F4){ref-type="fig"}\]. Tumor was positive for glial fibrillary acidic protein \[[Figure 4c](#F4){ref-type="fig"}\], and negative for LCA, pancytokeratin, and TTF-1 immunostain. Ultrasound-guided fine-needle aspiration (FNA) biopsy of the thyroid nodule was performed and specimen was sent to pathology. Sections from the FNA demonstrated classic papillary structures with fibrovascular cores covered by thyroid epithelium with pale chromatin, distinctly dissimilar from the brain tumor. The patient has been concurrently diagnosed with PTC \[[Figure 5a](#F5){ref-type="fig"}--[c](#F5){ref-type="fig"}\].

![Representative histology (GBM) of the tumor on hematoxylin and eosin-stained sections (a and b) show a cellular neoplasm with moderate pleomorphism (marked with blue arrow) and infiltrative growth. Areas of necrosis (marked with black arrow) are present (b). Immunochemistry is strongly positive for glial fibrillary acidic protein (marked with an arrow) (c)](JNRP-6-241-g004){#F4}

![Direct smears of the thyroid FNA stained with DiffQuick showed numerous sheets of epithelial cells (marked with an arrow), some in small papillary shaped aggregates with fine chromatin, small peripherally placed nucleoli, and nuclear grooves. Occasional nuclear inclusions were also present (a). Sections from the FNA cell block (b and c) demonstrated classic papillary structures with fibrovascular cores (blue arrow) covered by thyroid epithelium (black arrow) with pale chromatin, distinctly dissimilar from the brain tumor](JNRP-6-241-g005){#F5}

Discussion {#sec1-3}
==========

The Surveillance, Epidemiology, and End Results (SEER) study by Hayat *et al*. analyzed the cancer statistics data from 1973 to 2003 on multiple primary malignancies.\[[@ref1]\] They found that the primary index cancer with highest second primary cancers is urinary bladder (16%), followed by oral cavity and pharynx (15%) and corpus and uterus (11%). Canchola *et al*. highlighted the occurrence of non-invasive cancers such as *in-situ* breast cancer, renal cancer, and melanoma in patients diagnosed with thyroid cancer.\[[@ref2]\]

In U.S. Surveillance, Epidemiology and End-Results (SEER) cancer registry (1973-2000), 2,036,597 patients diagnosed with any invasive cancer showed a 42% increased risk for second thyroid cancer when compared to the general population.\[[@ref3]\] Patients younger than 40 years of age at the time of diagnosis of thyroid cancer had a 39% increased risk of a second cancer, whereas the risk was 6% in older patients.\[[@ref3]\] The author suggested etiologic similarities and possible treatment effects as culprits for the positive associations between thyroid cancer and, cancers of the brain, breast, prostate, kidney, salivary glands and leukemia.\[[@ref3]\]

PTC is the most commonly seen thyroid malignancy, affecting young women less than 45 years age, three to four times greater than men, and 5% of them occurring in childhood and adolescents.\[[@ref7]\] The well-known risk factors for thyroid cancer is exposure to ionizing radiation and family history of cancer syndromes. GBM can occur in people of any age, but they are more frequent in older adults. The risk factors for gliomas development include exposure to chemical carcinogens in occupations such as rubber manufacturing, petroleum production, vinyl chloride, pesticides, forestry work and cleaning services, exposure to therapeutic ionizing radiation, and passive smoking exposure.\[[@ref8]\] About 5% of gliomas represents familial aggregations, with some seen in known brain tumor syndromes such as Cowden\'s disease, Li-Fraumeni syndrome and neurofibromatosis.\[[@ref9]\] Most genetic alterations that seem to develop GBM involve intracellular signaling pathways such as receptor tyrosine kinases, Ras, TGF-β, TP53, RB1 and PTEN.\[[@ref10]\]

Initially, our patient presented with neurological symptoms and we may consider GBM as a primary index cancer. She did not have any risk factors for thyroid cancer apart from being young woman. The papillary thyroid cancer can be considered second primary cancer as it was diagnosed co-incidentally while searching for the primary cancer for suspected brain metastasis. Sandeep *et al*. highlighted the increased risk of thyroid cancer after various primary cancers.\[[@ref11]\] The author also concluded that thyroid cancer patients had a 30% increased risk of getting second primary cancer when compared to general population after analyzing the data from 13 cancer registries. Similarly, Canchola *et al*. reported that patients who had survived after thyroid cancer were more susceptible to have secondary malignancies, attributing it to their younger age and the good prognosis of the thyroid cancer.\[[@ref2]\]

Ogasawara *et al*. reported a case of 27 year-old Japanese woman found to have five primary malignant tumors namely bilateral breast cancer, primary papillary adenocarcinoma of right lung, and PTC along with GBM within span of 5 months.\[[@ref6]\] Chen *et al*. identified the aberrant expression of platelet-derived growth factor (PDGF) - A and PDGF receptor - α in both follicular thyroid carcinoma and PTC. When PDGF receptor - α binds to ligand, aquires a kinase activity which is associated with the multiple cancers, including astrocytomas, oligodendrogliomas, and glioblastoma.\[[@ref12]\]

Conclusion {#sec1-4}
==========

Physicians should maintain high surveillance for second primary cancers at a variety of sites in patients who have been found or treated for primary cancers, especially at young age. Further evaluation of genetic and environmental factors between papillary thyroid cancer and glioblastoma multiforme will improve our understanding of the etiology of these malignancies.
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